Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study.

ABSTRACT:

Background

Tetrabenazine (TBZ) is commonly used in hyperkinetic movement disorders. In this retrospective study, we aimed to assess the TBZ effectiveness and adverse events (AEs) in Huntington disease (HD), vascular chorea, tics, dystonia, tardive oromandibular (OM) dyskinesia and other tardive syndromes (TS).

Methods

Qualitative analysis of clinical response was used to estimate TBZ effectiveness. TBZ-associated AE frequency and subsequent discontinuation rate were used to estimate tolerability; the tolerability profile was measured through the TBZ minimal dose and exposure time required to elicit AEs.

Results

Of 108 included patients, 87% had a clinically meaningful improvement sustained over a period of 40 months. TBZ-responder rate ranged from 100% in HD to 62.5%

SUBMITTER: Miguel R 

PROVIDER: S-EPMC5367646 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature